Evidence map›Paper›PMID 34888307›Full record

ArticleFrontiers in cell and developmental biology2021

The Dysferlin Transcript Containing the Alternative Exon 40a is Essential for Myocyte Functions.

Océane Ballouhey, Sébastien Courrier, Virginie Kergourlay, Svetlana Gorokhova, Mathieu Cerino, Martin Krahn, Nicolas Lévy, Marc Bartoli

Open access · goldAbstract read
In one paragraph

Article in Frontiers in cell and developmental biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
3.3field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 29 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Océane BallouheyINSERM, MMG, U1251, Aix Marseille University, Marseille, France.
Sébastien CourrierINSERM, MMG, U1251, Aix Marseille University, Marseille, France.
Virginie KergourlayINSERM, MMG, U1251, Aix Marseille University, Marseille, France.
Svetlana GorokhovaINSERM, MMG, U1251, Aix Marseille University, Marseille, France.
Mathieu CerinoINSERM, MMG, U1251, Aix Marseille University, Marseille, France.
Martin KrahnINSERM, MMG, U1251, Aix Marseille University, Marseille, France.
Nicolas LévyINSERM, MMG, U1251, Aix Marseille University, Marseille, France.
Marc BartoliINSERM, MMG, U1251, Aix Marseille University, Marseille, France.
Inserm · FRAix-Marseille Université · FRHôpital d'Enfants · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Dysferlinopathies are a group of muscular dystrophies caused by recessive mutations in the DYSF gene encoding the dysferlin protein. Dysferlin is a transmembrane protein involved in several muscle functions like T-tubule maintenance and membrane repair. In 2009, a study showed the existence of fourteen dysferlin transcripts generated from alternative splicing. We were interested in dysferlin transcripts containing the exon 40a, and among them the transcript 11 which contains all the canonical exons and exon 40a. This alternative exon encodes a protein region that is cleaved by calpains during the muscle membrane repair mechanism. Firstly, we tested the impact of mutations in exon 40a on its cleavability by calpains. We showed that the peptide encoded by the exon 40a domain is resistant to mutations and that calpains cleaved dysferlin in the first part of DYSF exon 40a. To further explore the implication of this transcript in cell functions, we performed membrane repair, osmotic shock, and transferrin assay. Our results indicated that dysferlin transcript 11 is a key factor in the membrane repair process. Moreover, dysferlin transcript 11 participates in other cell functions such as membrane protection and vesicle trafficking. These results support the need to restore the dysferlin transcript containing the alternative exon 40a in patients affected with dysferlinopathy.

Indexed as

calpain (CAPN)dysferlindysferlinopathiesmembraneneuromuscular disease

Identifiers

PMID34888307
PMCPMC8650162
OpenAlexW3217627522

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.